Increased antimicrobial resistance during the COVID-19 pandemic
Journal
International journal of antimicrobial agents
Journal Volume
57
Journal Issue
4
Date Issued
2021-04
Author(s)
Abstract
In addition to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection itself, an increase in the incidence of antimicrobial resistance poses collateral damage to the current status of the COVID-19 (coronavirus disease 2019) pandemic. There has been a rapid increase in multidrug-resistant organisms (MDROs), including extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae, carbapenem-resistant New Delhi metallo-β-lactamase (NDM)-producing Enterobacterales, Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus (MRSA), pan-echinocandin-resistant Candida glabrata and multi-triazole-resistant Aspergillus fumigatus. The cause is multifactorial and is particularly related to high rates of antimicrobial agent utilisation in COVID-19 patients with a relatively low rate of co- or secondary infection. Appropriate prescription and optimised use of antimicrobials according to the principles of antimicrobial stewardship as well as quality diagnosis and aggressive infection control measures may help prevent the occurrence of MDROs during this pandemic.
Subjects
Antibiotic usage; Antimicrobial resistance; COVID-19; Multidrug-resistant organism
SDGs
Other Subjects
aminoglycoside antibiotic agent; amoxicillin plus clavulanic acid; antiinfective agent; azithromycin; beta lactamase inhibitor; ceftriaxone; cephalosporin derivative; colistin; daptomycin; fosfomycin; linezolid; moxifloxacin; polypeptide antibiotic agent; quinoline derived antiinfective agent; tigecycline; antiinfective agent; Acinetobacter baumannii; antibiotic resistance; antimicrobial stewardship; Aspergillus fumigatus; Burkholderia cepacia; Candida glabrata; carbapenem resistant New Delhi metallo beta lactamase producing Enterobacterales; carbapenem-resistant Enterobacteriaceae; coronavirus disease 2019; disease course; drug use; drug utilization; extended spectrum beta lactamase producing Klebsiella pneumoniae; human; incidence; infection control; methicillin resistant Staphylococcus aureus; mixed infection; Morganella morganii; multi triazole resistant Aspergillus fumigatus; multidrug resistance; nonhuman; pan echinocandin resistant Candida glabrata; pandemic; prescription; priority journal; Pseudomonas aeruginosa; Review; secondary infection; Severe acute respiratory syndrome coronavirus 2; Stenotrophomonas maltophilia; Taiwan; bacterial infection; bacterium; complication; drug effect; fungus; mixed infection; mycosis; pandemic; Anti-Bacterial Agents; Antimicrobial Stewardship; Bacteria; Bacterial Infections; Coinfection; COVID-19; Drug Resistance, Microbial; Drug Utilization; Fungi; Humans; Incidence; Mycoses; Pandemics
Type
review